Ukutya kwezoNyango zokuShatshazwa
I-Limbrel ligama legama le-flavocoxid, imithi "yokutya kwezonyango." Yenziwe ngokuhlanganiswa kwengcambu kunye neengcambu zeengcambu ezivela kwizityalo. Izicatshulwa zezityalo ziqukethe izinto ezibizwa ngokuthi i-flavonoids kwiinkxalabo eziphezulu awukwazi ukufumana ukutya okuqhelekileyo.
Ezinye ze-flavonoids ezifanayo zifumaneka kwikhoyi yamayeza e-Chinese ehlaza, esetyenziswe kunyango lweemeko ezahlukeneyo zonyango kwimbali ende.
Zifumaneka kwakhona kwi-kale, i-cocoa, i-apricot, i-cauliflower, i-soy kunye ne-peanutes. KwiLimbrel, i-flavonoids ephezulu i-baicalin ne-catechin. Njengokutya kwezokwelapha, iLimbrel ayifumanekanga kuluntu jikelele kodwa kunokuba imiselwe izigulane ezinokuthi ziphathwe yiimeko. Isibonakaliso samanje seLimbrel singokulawulwa kwe- osteoarthritis .
Ingaba isebenza kanjani
Amacwecwe e-flavonoid atholakala kwiLimbrel kubonakala enesakhiwo esichaphazelayo ngokukhubaza i-enzyme ebangela ukuvuvukala. Ezi enzymes, ezibizwa ngokuthi i-COX (cyclooxygenase) kunye ne-LOX (lipooxygenase) zenza iamolekyu ezibangela ukuvuvukala nentlungu.
I-Limbrel iyakuvimbela ukuveliswa kwezi enzyme kwaye ngoko kunciphisa ukuvuvukala kwezi zine-enzyme ziza kubangela. Ayinayo i-COX-2 inhibition yokukhethwa kwamanye amayeza e-arthritis. Ngezenzo ezimbini kwi-COX kunye ne-LOX, kunemiphumo embalwa kwimiphumo yesisu, intliziyo okanye iintso.
Iinkcazo
Isibonakaliso samanje sokumisela iLimbrel kukulawulwa kwezonyango zendlela yokutya ye-osteoarthritis. Inokumiselwa ukuba i-osteoarthritis ibe nzima. Akufanele kunikelwe kubantu abanomdla wokungenwa kwe-flavocoxid okanye i-flavonoids.
Ukuba unesiqhelo kwizinto eziqhelekileyo eziphezulu kulezi zinto, ezifana ne-tea ehlaza, i-tsholethi emnyama, iwayini elibomvu okanye amanqamzana aseBrazil ugqirha wakho unokugqiba isigqibo sokuba angabhalisi iLimbrel.
Angafundwanga ngokusemthethweni kubantu abaneminyaka engaphantsi kwe-18 okanye abasetyhini abakhulelweyo okanye abancelisayo, ngoko akukhuthazwa ngabo bantu.
Isistim
I-Limbrel kunye neLimbrel500 banikwa ngomlomo njengethebhulethi, kabini ngosuku. Kukho amafomula amabini, 250 mg kunye ne-500 mg. Bobabini banama-50 mg we-citrated zinc bislycinate. I-Limbrel yinto yokugonywa ngamayeza okumele isetyenziswe phantsi kolawulo lwegqirha.
Imiphumela
I-FDA ibeka iLimbrel njengesidlo sezonyango. Inikwa njengomyalelo, kodwa oku kudla "kuye kwaqatshelwa ukuba kukhuselekile" yi-FDA. Nangona kunjalo, ukutya kwezokwelapha akuhambanga ngokukhuseleko olusemthethweni kunye nokuvavanya ngempumelelo njengokuba iziyobisi kufuneka zidlule ngaphambi kokuba zibekwe kwiimarike. Baqhubeka nokujonga ukukhangisa emva kokuthengisa kunye nemiphumo emibi.
I-Limbrel ayifumananga ukuba neempembelelo ezibhekiselwe kwiimithi ezichasayo ezingabhubhisiyo (i-NSAID), kuquka neengxaki ngokubunjwa kwezilonda zesisu. I-Limbrel ineempembelelo ezinjenge-placebo (ipilisi yeshukela). Uphando lufumene njengolusebenzayo njenge naproxen kodwa lukhuseleko olungcono lwezondlo, isisu kunye nemiphumo yokuphefumula.
Iziganeko ezine zesalathiso esibi kakhulu ezinxulumene neLimbrel zachazwa ngovavanyo luka-2010.
Ukutya kwezoNyango ngokumalunga neZondlo zeDiary
Amagama athi "ukutya kokutya" kunye "nesongezelelo sokutya" ahluke kwimimiselo yabo yi-FDA.
Ukutya kwezokwelapha:
- inikezela ngenkxaso yesondlo ngesifo okanye imeko ethile,
- kwaye ihloselwe ukuba isetyenziswe phantsi kolawulo lonyango.
Isitshixo kukuba "ukutya kokonyango" kuklanyelwe ukulawula isifo esithile okanye imeko (umz. Limbrel for arthritis), kanti "izongezo zokutya" zenzelwe ukuxhasa umsebenzi ophilileyo wenxalenye yomzimba (umzekelo, i-glucosamine ye-cartilage yezempilo).
Imithombo:
Martel-Pelletier J, et al. Umsebenzi wokwelapha wee-inhibitors ezimbini ze-5-LOX kunye ne-COX, i-Selective ne-Non-Selective Non-Steroidal Anti-Inflammatory Drugs. " Ann Rheum Dis. 2003 Juni; 62 (6): 501-9.
Leval X, et al. "Imizila emitsha ku-5-LOX / COX Inhibition." Curr Med Chem. 2002 ngoMeyi; 9 (9): 941-62.
Limbrel.com
N. Chalasani, R. Vuppalanchi, V. Navarro, R. Fontana, H. Bonkovsky, H. Barnhart, DE Kleiner kunye noJH Hoofnagle. "Ukuxakeka kobungozi obubi ngenxa yeFlavocoxid (iLimbrel), ukutya kwezoNyango kwi-Osteoarthritis. I-Series Series. "Ama-Annal of Medicine Internal 19 Juni 2012 (umqulu 156, iphepha 857-860).
RM Lev, Khokhlov A, Kopenkin S, Bart B, Ermolova T, Kantemirova R, Mazurov V, Bell M, Caldron P, Pillai L, Burnett BP. "Ukusebenza kunye noKhuseleko lwe-Flavocoxid, i-N ovel Therapeutic, eyafaniswa ne-Naproxen: Uvavanyo oluLungelelanisiweyo oluLungelelanisiweyo kwiZifundo kunye ne-Osteoarthritis ye-Knee." Adv Ther. 2010 Oct; 27 (10): 731-42. i-doi: 10.1007 / s12325-010-0064-z